- Home
- MTR vs KZIA Comparison
MTR vs KZIA Comparison
Compare MTR & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTR
- KZIA
- Stock Information
- Founded
- MTR 1979
- KZIA 1994
- Country
- MTR United States
- KZIA Australia
- Employees
- MTR N/A
- KZIA N/A
- Industry
- MTR Oil & Gas Production
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- MTR Energy
- KZIA Health Care
- Exchange
- MTR Nasdaq
- KZIA Nasdaq
- Market Cap
- MTR 10.9M
- KZIA 11.7M
- IPO Year
- MTR N/A
- KZIA 1999
- Fundamental
- Price
- MTR $5.86
- KZIA $8.68
- Analyst Decision
- MTR
- KZIA Strong Buy
- Analyst Count
- MTR 0
- KZIA 2
- Target Price
- MTR N/A
- KZIA $14.00
- AVG Volume (30 Days)
- MTR 7.1K
- KZIA 675.5K
- Earning Date
- MTR 01-01-0001
- KZIA 08-12-2025
- Dividend Yield
- MTR 3.60%
- KZIA N/A
- EPS Growth
- MTR N/A
- KZIA N/A
- EPS
- MTR 0.23
- KZIA N/A
- Revenue
- MTR $668,826.00
- KZIA $1,549,158.00
- Revenue This Year
- MTR N/A
- KZIA N/A
- Revenue Next Year
- MTR N/A
- KZIA $49.25
- P/E Ratio
- MTR $25.79
- KZIA N/A
- Revenue Growth
- MTR N/A
- KZIA 248983.08
- 52 Week Low
- MTR $4.70
- KZIA $2.86
- 52 Week High
- MTR $10.42
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- MTR 55.20
- KZIA 50.61
- Support Level
- MTR $5.47
- KZIA $7.40
- Resistance Level
- MTR $5.98
- KZIA $10.08
- Average True Range (ATR)
- MTR 0.23
- KZIA 0.78
- MACD
- MTR 0.02
- KZIA -0.29
- Stochastic Oscillator
- MTR 84.21
- KZIA 42.38
About MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.